Science

Emre Yekedüz: Adding 6 months of ADT to SBRT significantly improved clinical PFS compared to SBRT alone

lifelinecelltech.com

Mar 7, 2025, 03:20

Emre Yekedüz: Adding 6 months of ADT to SBRT significantly improved clinical PFS compared to SBRT alone

Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University, shared an article by Giulia Marvaso, et al. on X:

“In patients with metachronous oligorecurrent hormone-sensitive Prostate Cancer, adding 6 months of ADT to SBRT significantly improved clinical progression-free survival compared to SBRT alone!

Phase 2, randomized trial.
105 patients, single-center (European Institute of Oncology, Milan).
SBRT (30 Gy/3 fx) ± 6 months ADT.”

ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial.

Authors: Giulia Marvaso, et al.

Emre Yekedüz: Adding 6 months of ADT to SBRT significantly improved clinical PFS compared to SBRT alone

Ankara University cancer Emre Yekedüz European Institute of Oncology fight against cancer Giulia Marvaso Global fight against cancer MedOnc OncoDaily Oncology prostate cancer SBRT

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action

King Hussein Cancer Research Award: Don’t Miss Your Chance to Apply